Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

NEUPRO 8 MG / 24 HOUR

ROTIGOTINE : 8 MG / 24 HOUR · DIN 02403943 · UCB CANADA INC

Health Canada status: MARKETED

What is NEUPRO?

NEUPRO 8 MG / 24 HOUR contains ROTIGOTINE : 8 MG / 24 HOUR. It is listed in the Health Canada Drug Product Database under DIN 02403943, held by UCB CANADA INC, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 27-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is NEUPRO used for?

Treatment of signs and symptoms of idiopathic Parkinson’s disease (early or adjunct to levodopa) and symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02403943
Brand nameNEUPRO
Generic / active ingredientROTIGOTINE : 8 MG / 24 HOUR
ManufacturerUCB CANADA INC
Strength8 MG / 24 HOUR
Dosage formPATCH
Route of administrationTRANSDERMAL
SchedulePrescription
ATC codeN04BC09 ROTIGOTINE
AHFS class28:36.20.08
BiosimilarNo
Health Canada statusMARKETED
Status date27-Jun-2013
Original market date2013-06-27 00:00:00

How is it administered?

Administered once daily. Application site should be rotated daily; same site should not be used within 14 days. Taper treatment during discontinuation to avoid withdrawal symptoms.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly stated in the provided text (Summary Product Information and Storage sections are referenced but values are missing in the snippet).

How is it supplied?

Six strengths (1, 2, 3, 4, 6, 8 mg/24h). Specific packaging configurations (e.g. bottles/cartons) not detailed in provided text snippet beyond patch sizes.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Warnings and precautions

Sudden onset of sleep; orthostatic hypotension; syncope; elevations in BP/heart rate; fluid retention/weight gain; hallucinations; impulse control disorders; application site reactions; melanoma risk.

What can be used instead?

Other Canadian products sharing ATC code N04BC09 ROTIGOTINE. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
NEUPRO1 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403897
NEUPRO2 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403900
NEUPRO3 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403919
NEUPRO4 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403927
NEUPRO6 MG / 24 HOURPATCHUCB CANADA INCMARKETEDDIN 02403935

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for NEUPRO

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for NEUPRO

Health Canada Drug Product Database (DPD), DIN 02403943. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.